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Precision medicine represents a modern transition toward utilizing patient 
genetics to create specific, individualized treatment options for a variety of diseases. To 
demonstrate the significance of personalized patient care, we can examine the variation 
in responses to drugs among genetic variants of the same species. Caenorhabditis 
elegans (C. elegans) is a model organism for human research, beneficial for collecting 
mass data from genetically identical individuals due to their hermaphroditic 
reproduction and relatively short lifespan. Experimentation with the nematode species 
C. elegans and drug applications may suggest variability in effects when examining 
different strains or slight genetic variants. Differences in drug or compound 
effectiveness among strains of the same species would indicate the importance of 
individualized care to maximize positive outcomes. In this experiment, we analyzed the 
lifespans of four strains of C. elegans when exposed to the antioxidant compound, 
resveratrol, compared to a control with no compound. Resveratrol is known to extend 
the nematode lifespan in wild-type or “non-mutant” lines. We also examined mutant 
lines of these four strains, each with the daf-16 transcription factor gene knocked-out 
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through CRISPR technology. These mutant lines underwent the same procedures as 
their corresponding wildtype strains to compare lifespan changes between control and 
resveratrol exposure. The magnitude of difference in drug effectiveness among 
individuals of the same species indicates a need to investigate genetic variation and 
personalize treatment plans that are more efficient and effective. 
As a passionate Human Physiology major with a long-term goal of working in 
medicine, I am always captivated by the transitioning platform for medical care. The 
advancements in science pave way for greater disease prevention and treatment with the 
potential of bettering the lives of countless individuals. This Clark Honors College 
thesis through the University of Oregon is a compilation of current personalized 
medicine research with the goal of analyzing the innumerable possibilities and potential 
future directions of Westernized medicinal care. Furthermore, the body of my thesis 
will include personal research conducted through an Ecology and Evolution laboratory 
to examine lifespan differences among strains of the roundworm Caenorhabditis 
elegans exposed to an antioxidant compound. The goal is to better understand the 
interactions between genetic makeup and drug responsiveness. This will provide 
correlative evidence and implications surrounding the importance of personalized 
treatments in humans, and provides the basis for examining the necessary 
considerations and conditions required to transition toward individualized care, 
including components beyond genetic analysis and targeting disease as well as the risks 
and ethical concerns surrounding the future of personalized medicine.  
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Introduction 
Personalized medicine encompasses a variety of diagnosis and treatment 
techniques, all of which target specific types of diseases predicated upon differences 
among individual patients. Important consideration factors include health status, age, 
medical history, genetic profile and individual environment. Some aspects of modern 
medicine are slowly making the transition toward cell and gene therapies for many 
disease-treatment models, specifically in genetic or rare diseases. This individualized 
care has received a great deal of attention in the medical community in recent years. 
The interest in prevention, diagnosis and treatment modalities targeted to specific 
diseases based upon individual patient variability has sparked a discourse about and 
innovation in the science community. Most recently, cell and gene therapies for cancer 
and gene therapy for severe combined immunodeficiencies have proved highly valuable 
and effective therapies in various experimental and some clinical settings (Bauer, 2017). 
Genetic analysis is key in these cases. When combined with a holistic understanding of 
the patient as an individual entity, the likelihood for health increase and disease 
elimination grows substantially.  
The modern medical system involves physicians diagnosing disease to then 
formulate plans to improve quality of life. However, many modern treatments are 
primarily based on what will help the average individual rather than extensively 
analyzing the individual patient in need. Every person has a unique variation of the 
human genome, and this genetic variation can play a large role in individual health, 
especially when combined with distinct behavior and unique influences from the 
environment. Individual genotype or genetic makeup dictates unique phenotype, the 
Commented [TC1]: CITATION 
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observable characteristics. One idiosyncratic demonstration of biological variation 
among people occurs in individual drug responsiveness. Because DNA encodes for 
proteins and drugs interact directly with proteins, the genetic makeup of an individual 
can directly impact how a drug interacts with the body. Many of the current 
prescriptions and treatment options are standardized for what works for the average in 
prior medical trials. For example, it has been shown that ADHD medicine only works 
for one out of ten preschoolers, many of the most widely used cancer drugs are effective 
for about 25% of patients, and typical depression drugs have a success rate of only 60% 
(Goldstein, 2005). With the availability of genetic analysis technology and a greater 
understanding of the components that affect human health, modern medicine is slowly 
transitioning to personalized care to create both prevention and treatment plans. As 
technology advances in this manner, medical research must focus on the factors that 
influence drug effectiveness among individuals diagnosed with the same disorder. Due 
to the impossibility of analyzing a large subset of humans with identical genomes, 
environmental factors and lifestyle choices, there is a call to utilize model organisms 
such as Caenorhabditis elegans to understand the implications of such factors on 
medical diagnosis and treatment.  
One principle of personalized medicine is the treatment of patients based on 
identification of genetic mutations or abnormalities that cause disease, providing 
treatment options based on an individual’s genetic makeup. This personalized, precision 
treatment is based on a single patient system rather than utilizing general disease 
diagnoses, leading to a higher probability of therapeutic success and likely increased 
cost efficiency in the healthcare sector. Genome sequencing, analyzing the genetic Commented [TC2]: Repeating what was just said, maybe fix to be a new point?  
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makeup of an individual, can function to diagnose disease while also playing a role in 
drug prescription and dosage allotment. Drug effectiveness can depend on genetic 
background, as an individual’s DNA encodes for proteins that have receptors for 
specific drugs that aid in their transport or function as enzymes for important bodily 
reactions. The precision medicine movement could allow detection of known protein 
markers (called biomarkers) in individuals, giving physicians insight to cater drug type 
and dosage based on what will be most efficiently utilized by the individual’s body 
(Abou-El-Enein, 2017). Because drugs and treatments interact directly with human 
proteins, understanding individual make-up in pivotal in efficient medical care. 
Analyzing protein-protein interactions and understanding the genome’s role in disease 
pathways will lead to a greater ability to directly treat individuals based on their unique 
characteristics. The importance of medical research using model organisms is immense 
in this area, as many molecular pathways are conserved among organisms.  
These transitions have brought significant commercialization challenges to the 
surface, however, driven by high developmental costs and difficulties surrounding 
circulation of genetic information and the diagnostic results based off them. The 
increasing development of technology, especially in the westernized world, has 
potential to change the modern medical techniques to cater care for an individual and 
his or her individual ailment. Troubles arise when the rapidly changing technological 
advances surpass the experimental and clinical trials. Many of the difficulties 
surrounding the adoption of a personalized medical approach stem from the lagging 
clinical trials and policy development around the quickly rising technological 
possibilities. It is important to recognize and address these obstacles while evaluating 
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the future of modern medicine and the possibilities genomic analysis can provide. 
Individualized, personalized, precision medicine has the potential to become the most 
efficient and effective medicine model science can offer and with the considerations of 
the pitfalls and difficulties in the transition, it is imperative that physicians cater 
therapeutic techniques to each individual patient holistically by utilizing the genomic 
technology readily available.  
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Background Information 
 The human genome consists of approximately 3 billion nucleotide base pairs 
bound in a molecular strand called deoxyribonucleic acid (DNA), coiled into 23 pairs of 
chromosomes residing in the nucleus of every cell. Each of these chromosomes contains 
hundreds to thousands of genes with specific instructions to make RNA which then can 
translate and produce proteins. Humans have an estimated 30,000 genes that encode 
proteins and each of these genes, on average, can make three proteins (Human Genome 
Project). In 1988, the Human Genome Project was created by a committee of the U.S. 
National Academy of Sciences, working with the National Institutes of Health and the 
Department of Energy to create physical and genetic maps of the human genome. They 
successfully mapped the first complete human genome in 2003 and was made readily 
available to the public (Human Genome Project). Since the completion of this genetic 
mapping, scientists have been developing new technologies to interoperate and 
understand the human sequences in the context of medical advances and improving 
human health (Human Genome Project). 
Important steps in genome-based research have been ongoing the last ten years 
in attempts to understand how parts of the genetic code work together in various 
pathologies. As genome sequences techniques are becoming faster, less expensive and 
more readily accessible, the development of diagnostic tools based, in part, on genetic 
sequences will lead to a powerful form of preventive medicine and disease treatment 
techniques (Human Genome Project). Determining protein biomarkers is an imperative 
part of the process to streamline efficient and effective care. Regions in the human 
genome correspond to specific proteins and biochemical pathways that could help 
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physicians locate the root cause of disease or dysfunction (Schork, 2015). They 
accurately and reproducibly represent a quantifiable biological characteristic, giving an 
objective measure of disease or overall health status (Skevaki, 2015). By measuring the 
protein biomarker availability and responses, genetic characteristics can be inferred and 
specifically targeted for effective therapy. Physicians can use this tool to better 
understand disease processes, allowing for early detection, treatment and disorder 
management, especially in the context of noncommunicable diseases (NCDs). These 
chronic disease, such as cardiovascular disease, cancer, chronic respiratory disease and 
diabetes are prevalent worldwide, with every 3 deaths each year attributed to an NCD 
(Skevaki, 2015).  
A Personalized Approach 
Researchers have discovered hundreds of genes with variations or mutations 
contributing to a variety of human illnesses. It has also been determined that treatments 
of many diseases have varied results, due in part to genetic variability in patients. This 
demonstrates the importance of targeting the molecular causes of some diseases, using 
diagnostic tests based on genetics or other molecular mechanisms for more effective 
and efficient therapies catered to the individual (Hamburg, 2010). Many of the current 
leaders in medical interventions including the National Institutes of Health (NIH) and 
the Food and Drug Administration (FDA) have begun the transition toward a 
personalized medicine approach. The overall goal is to focus on the best mechanism of 
therapy development to optimize correct drug administration and the right time with the 
right dose (Hamburg, 2010). 
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Determining the most clinically significant genetic markers has proven difficult 
and the development of policy surrounding such a novel approach to patient care leads 
to a myriad of challenges. The treatment itself, determined by a personalized and 
genetic analysis approach, will vary depending on the circumstances and results may 
inform a need for diet or lifestyle changes, specific drug treatments or possibly medical 
surveillance (Human Genome Project).  
The term precision medicine has also been used in the context of focusing 
clinical applications on the individual rather than the average human. Among the top ten 
highest-grossing drugs in the United States, the likelihood that the therapy actual helps 
an individual is between 1 in 25 and 1 in 4, thus the most popular drugs have less than 
25% efficiency (Schork, 2015). Some drugs, such as statins to routinely lower 
cholesterol, benefit as few as 1 in 50. Others are even harmful to certain ethnic groups 
because of the bias towards white Western participants in experimental studies (Schork, 
2015). Because the data collected in many of the therapeutic drug trials are controlled 
on factors like genetics, lifestyles and diets, the results may indicate the need to study 
and validate the effectiveness of therapy in those that responded positively to determine 
the biological mechanisms (Stenson, 2014). An article in a 2015 issue of Nature 
entitled, “Personalized medicine: Time for one-person trials”, includes data showing the 
ten highest-grossing drugs in the United States and the number of people they help with 
each prescription demonstrate this dramatic difference in drug effectiveness. It shows 
that the top drugs in the nation prescribed by medical professionals fail to improve 
conditions of between 3 and 24 people for every person they do benefit. This table is 
labeled “imprecision medicine”, showing the ineffectiveness of the most popular drugs 
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and emphasizing the need to transition towards a precision medicine practice, providing 
personalized prevention and treatment for patients. 
Inherited diseases account for up to 70% of all admissions to children’s hospitals 
and 10% of admissions to adult hospitals. Many of the most common inherited 
disorders like cystic fibrosis and sickle cell anemia lack treatments beyond supportive 
care. Several modes of gene therapy allow for the manipulation of genetic mutations to 
correct the known genetic causes of various inherited diseases (Mingozzi, 2011). Two 
of the most common gene therapy treatments utilize either the transfer of stem cells—
with the potential to differentiate into selected tissues—or utilization of viral machinery 
to manipulate the human genetic code. Some diseases showing promising gene therapy 
outcomes have included cystic fibrosis, hemophilia, heart failure and Parkinson’s 
disease (Mingozzi, 2011). Cardiovascular disease (CVD) treatment is one area that 
would benefit greatly from the transition to personalized medical care, as CVDs remain 
the leading cause of death in the United States (Lee, 2012).  
Many studies are identifying genetic variations underlying risks of both rare and 
common diseases, providing information for newly discovered genes, proteins and 
pathways that may be powerful drug targets. Today, however, there is insufficient 
evidence or identification of potential therapeutic targets for many of these diseases. 
Academic researchers, including many NIH-supported centers, must screen thousands 
of chemicals to find potential drug candidates for commercial development (Hamburg, 
2010). With the more personalized approach, development in genetic informatics must 
match up with the pharmaceutical and biomedical technologies as well. To do so, a 
collaborative approach would be imperative. Utilizing the model organism 
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Caenorhabditis elegans, it is possible to isolate genetic differences to determine their 
role in drug effectiveness, keeping all environmental factors consistent and analyzing 
many organisms in a short timeframe. To effectively transition to personalized care, the 
interplay of genetics and therapeutic treatment needs to be better understood. 
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Experimental Findings: Caenorhabditis elegans 
Experimental Background Information 
Caenorhabditis elegans is a model organism for studies in biological 
development, evolution and human diseases. It was the first multicellular organism to 
have its genome completely sequenced in 1998, thus there are more tools for genetic 
manipulation for this organism than nearly all others. Additionally, it is easy to culture 
and maintain in the lab with a rapid life cycle of 3 days from egg to egg-laying adult 
and an average lifespan of 18 to 20 days. Its microscopic size—approximately 1 
millimeter long—makes cultivation and environmental manipulations easy to manage 
(Balla, 2013). The animals can also be frozen for years and thawed when needed, 
important when reproducing experimental results and maintaining identical C. elegans 
lines for future use. Most important for this study, C. elegans is a self-fertilizing 
hermaphrodite, meaning a single animal can populate a plate and a single strain can be 
replicated with the same genetic makeup (Corsi, 2015). Within a single strain, all 
organisms are genetically identical, while across strains there are slight genetic 
differences, despite being members of the same species.   
There are numerous similarities in both cellular and molecular processes among 
C. elegans and other animals, including metabolism, organelle structure, gene 
regulation and protein biology. At least 38% of the C. elegans protein-coding genes 
have orthologs—pathways of similar genetic origin evolved by speciation retaining the 
same function—found in the human genome. Approximately 40% of genes with known 
association to human diseases have clear orthologs in the C. elegans genome (Balla, 
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2013). Consequently, research and results surrounding C. elegans is often translated to 
possible human outcomes, especially in the context of the newly developed precision 
medicine initiative. Because the genetic makeup across the human species can C. 
elegans is similar, the experimentation with the nematode can provide general trends 
that should be, to some degree, mirrored in human subjects. Furthermore, it is 
impossible to do large scale experimentation on genetically identical individuals 
utilizing mice, monkeys or humans. The utilization of C. elegans allows for 
reproducibility that other model organisms cannot provide.   
The genetic sequences are known for all observed strains and “knock-out” lines 
(with a genetic deletion of the daf-16 region) have been created with CRISPR-cas9 
editing technology, affecting an insulin-like pathway similar to that in humans. This 
deletion, or mutation, has been shown to decrease lifespan in the C. elegans. Similar 
pathways called insulin-like growth factors exist in other organisms, including 
mammals and humans, which carry out similar functions. In mammals, for example, the 
FOXO-transcription factor activates genes that mediate oxidative stress, heat shock, 
innate immunity and metabolism (Hesp, 2015). With an expected difference in lifespan, 
the drug effectiveness on the mutant strains may have a differing magnitude of change 
when compared to the non-mutant wild-type trials among each strain. To relate the 
mechanisms examined in C. elegans to human applications, studies have been 
conducted to determine orthologs—genes evolved from common ancestral trait—
between the species. In the case of the C. elegans DAF-16 pathway, humans have four 
homologous FOXO transcription factors that influence age-related disease such as 
cancer, osteoporosis and diabetes mellitus (Hesp, 2015). A greater understanding of the 
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DAF-16 transcription factor mediated stress responses in C. elegans increased insight 
into age-related disease. Recent research on components of the insulin-like signaling 
pathway—affecting metabolism and longevity—and DAF-16 in C. elegans has 
facilitated the discovery of protein homologs in humans, which regulate aging and 
many age-related diseases (Hesp, 2015). Observation of both the DAF-16 pathway and 
drug exposure on lifespan has not yet been conducted under this context, thus my 
experimentation will further explore the metabolic interactions of the pathway in C. 
elegans for human application as well.  
The examined C. elegans strains were exposed to an antioxidant compound 
called resveratrol, shown to elongate lifespan among various wild-type nematode strains 
and other model organisms. Resveratrol, with the chemical name tran-3,4’,5-
tridydorxystilbene, is a naturally compound found in the skin of various plants such as 
grapes and peanuts (Fischer, 2016). Many beneficial effects have been recently studied, 
including anti-inflammatory and antioxidant characteristics and modulation of different 
intracellular signaling pathways. Antioxidant activity and radical scavenging may be 
responsible for the life-prolonging effects of resveratrol, diminishing the amount of 
reactive oxygen species involved in aging (Fischer, 2016). It may also increase AMP-
activated protein kinase (AMPK) phosphorylation, regulating the SIRT1 pathway. 
Small molecule activators of this pathway have been developed as therapies for the 
treatment of type 2 diabetes, as AMPK helps cells uptake glucose independently of 
insulin (Farghali, 2013).  
Aging is often described as a risk factor for disease, but can be defined as a 
disease itself with a 100% mortality rate (Bulterijs, 2015). All individuals that are alive 
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and age eventually die. The medical definition of a disease is a “harmful abnormality of 
bodily structure and function” and aging most definitely falls into such a category. The 
causes of aging are becoming increasingly clear, most of which can be reduced to a 
cellular and molecular level with recognizable signs and symptoms like other 
commonly defined diseases and disorders (Bulterijs, 2015). In this experiment, 
nematode age is the dependent factor, with aging treated as a progressive disease and 
the administered compound as a disease prevention treatment. Analyzing the daf-16 
knock-out lines allow observation of compound effectiveness in organisms with 
accelerated disease symptoms, as the mutants lack an important transcription factor in 
an insulin-like pathway influencing longevity. With the environmental factors held 
constant, the effectiveness of the compound for aging treatment will be dependent 
solely on genetic variation across the C. elegans strains.  
Data analysis after experimentation will provide conclusions that may have 
implications to the recent precision medicine initiative. By determining the magnitude 
of lifespan variance between C. elegans with slight genetic difference given resveratrol, 
we can observe the importance of genetic consideration when administering drugs to 
humans in a clinical setting. The results from this experiment could emphasize the 
importance of genetic analysis in medical treatment.  
Purpose & Hypothesis 
The specific purpose of this experiment is to determine the variance in lifespan 
among four strains of Caenorhabditis elegans and mutant lines of each strain when 
exposed to the same compound, the anti-oxidant resveratrol. By determining the effects 
of drugs across slightly genetically different strains of the same species along with a 
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mutant variant of each strain, we can explore the relationship between drug 
effectiveness and genetic makeup. It is hypothesized that controlled resveratrol 
application to four C. elegans strains and their respective daf-16 mutants will result in 
varied changes in lifespan due to the slight genetic variability among strains and 
differential drug effectiveness.  
Methods 
The 4 Caenorhabditis elegans strains selected for this experiment included N2, 
JU775, CB4856 and MY16. Each strain is a unique C. elegans wild isolate originating 
from various geographic locations. Previously generated daf-16 mutants for these 
strains were also thawed and maintained in an identical manner, including PX591 
(N2∆), PX595 (JU775∆), PX597 (CB4856∆) and PX606 (MY16∆). Each mutant was 
genetically manipulated through CRISPR-cas9 technology and identical sequences were 
deleted from each strain to ensure homogeny.  
The worm strains utilized in this experiment were thawed from frozen stocks in 
a single lab and all standard operating procedures were followed in their growth and 
maintenance. This includes plate and drug preparations and allowing thawed worms to 
grow three generations before experimental use. All worm cultures were maintained at 
20°C with 80% humidity. Before placed on scanner plates, they were cultivated on 
nematode growth media (NGM). A streptomycin-resistant bacteria strain (OP50-1) 
was the food source for each plate throughout experimentation.  
Populations of the same age were obtained by three-hour egg lays with first-day 
adults, which were then removed while the eggs developed into the next generation 
adults. Upon the first day of adulthood, these worms were moved to NGM plates 
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containing the compound FUdR, inhibiting subsequent reproduction without changing 
the lifespan on the adult worms. Between 25 and 40 worms were transferred to FUdR 
plates with and without resveratrol application, allowing comparison between drug and 
control conditions. The resveratrol plates were prepared by dissolving the solid 
compound in dimethylsulfoxide (DMSO) to create a stock solution that could be added 
to sterile water before application. Specifically, 10.0μL of stock solution (40mM 
resveratrol in DMSO) was added to 166.7μL for each plate. The resveratrol 
concentration on each scanner plate with 7mL NGM was 100μM. This solution was 
distributed across the entire plate surface and allowed to dry in a sterile hood until all 
liquid was absorbed into the agar. Control plates also contained the same concentration 
and volume of DMSO.  
Lifespan data for the four hermaphroditic C. elegans strains and their respective 
daf-16 mutant lines was generated through an automated lifespan machine (ALM). The 
ALM is a set of modified high resolution scanners that collect images of worms on 
plates, typically collected every hour. The collected images are analyzed automatically 
by software that determines if a worm is dead or alive based on movement, as shown in 
Figure 1. 
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Figure 1: Automated lifespan machine imaging software 
The high-resolution image taken by the scanner is then analyzed by a software that 
detects subtle movements across the collected images. When worms have completely 
stopped moving, the ALM records time of death, which is then checked for each worm 
by hand after data collection is complete. A survival plot is generated, showing the 
percent of worms surviving over time.  
In this experiment, each ALM scanner held sixteen specialized plates with and without 
compound and approximately 40 worms on each plate. In the experimental duration, 
four scanners were utilized at the same time to ensure controlled environmental 
conditions. The plates were randomized on the scanner bay to avoid error due to 
unforeseen heat distribution or air flow in the experimental area. The room, however, 
was climate controlled due to the sensitivity of nematodes to temperature changes.  
The lifespan analysis of each worm was collected through the ALM 
programming and the time of death of each worm was confirmed by hand, evaluating 
the time at which each worm stopped all movement. Survival plots were generated 
automatically along with data for each plate. Exactly 1114 worms were examined in the 
lifespan data analysis, including all four strains and their respective mutants.  
 
 
17  
Figures  
 
Figure 2: Survival Plot for N2 and N2∆ 
 
Figure 3: Survival Plot for JU775 and JU775∆ 
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Figure 4: Survival Plot for CB4856 and CB4856∆ 
 
Figure 5: Survival Plot for MY16 and MY16∆ 
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Figure 6:  Median Lifespan  
This figure depicts the average median lifespans of all C. elegans strains and their 
respective mutant strains both with and without resveratrol.  
 
Figure 7: Resveratrol effectiveness among C. elegans strains. 
The percent variance from the control average median lifespan with exposure to 
resveratrol indicates the effectiveness of the compound in extending lifespan.  
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Tables 
Table 1: N2 and N2∆ ALM Data 
Data collected for N2, showing both the average lifespan and the median lifespan of the strain 
with and without drug. Also includes number of worms analyzed (n) for each condition.  
Table 2: JU775 and JU775∆ ALM Data 
Data collected for JU775, showing both the average lifespan and the median lifespan of the 
strain with and without drug. Also includes number of worms analyzed (n) for each condition. 
Number of worms Average Lifespan Median Lifespan 
Strain + Condition analvzed (n) (davs) (davs) 
N2CTRL 121 16.1331 16.343 
N2 Rsvtl 71 16.8875 17.582 
PX59 1 CTRL 45 12.6498 I 2.478 
PX59 1 Rsvtl 158 14.3051 14.135 
Combined 395 15.1406 14.885 
Number of worms Average Lifespan Median Lifespan 
Strain + Condition analvzed (n) (days) (days) 
JU775 CTRL IOI 15.7272 14.478 
JU775 Rsvtl 75 20.3196 21.54 1 
PX595 CTRL 64 14.032 13.905 
PX595 Rsvt l 57 16.062 1 16.635 
Combined 297 16.5859 15.749 
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Table 3: CB4856 and CB4856∆ ALM Data 
Data collected for CB4856, showing both the average lifespan and the median lifespan of the 
strain with and without drug. Also includes number of worms analyzed (n) for each condition.  
  
Table 4: MY16 and MY16∆ ALM Data 
Data collected for MY16, showing both the average lifespan and the median lifespan of the 
strain with and without drug. Also includes number of worms analyzed (n) for each condition. 
umber of worms Average Lifespan Median Lifespan 
Strain + Condition analvzed (n) (davs) (davs) 
CB4856 CTRL 80 19.023 1 18.6 19 
C84856 Rsvt l 106 20.5835 2 1.7 I 8 
PX597 CTRL 9 1 14.3319 1402 
PX597 Rsvtl 41 19.1754 20.30 1 
Combined 318 18.2204 18.098 
Number of worms Average Lifespan Median Lifespan 
Strain + Condition analyzed (n) (davs) (davs) 
MY l 6 CTRL 26 14.8578 14.78 
MYl 6 Rsvt l 69 19604 19.874 
PX606CTRL 8 16.3168 14.989 
PX606 Rsvtl 34 14.1919 14.093 
Combined 137 17.1681 15.833 
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Table 5: Average percent lifespan variance of all strains with exposure to resveratrol 
Results 
Resveratrol was shown to increase lifespan to some degree across all strains. 
The degree to which resveratrol affected C. elegans lifespan varied across the strains for 
both wild-type (WT) and mutant (daf-16). For example, of the WT strains, it was found 
that JU775 had the greatest percent difference from control median lifespan with 
resveratrol exposure, a 54.5% increase. In contrast, the WT strain N2 showed only a 
0.534% increase in lifespan with resveratrol application. The other WT strains CB4856 
and MY16 showed an increase in lifespan of 34.7% and 41.9% respectively.  
 The daf-16 mutants showed inconsistancy in resveratrol response across the 
strains as well, although to different degrees than their respective WT strains. The strain 
PX597 (CB4856∆) showed the most dramatic response to the compound with a 56.4% 
increase in median lifespan as compared to control conditions. Alternatively, the lowest 
Average Percent 
Strain Variance (%) Standard Error 
N2 0.534 17.36 
JU775 54.5 7.819 
CB4856 34.7 18.66 
MY16 41.9 12.99 
PX591 9.90 0.3131 
PX595 28.7 
PX597 56.4 0.54387 
PX606 0.486 
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percent variance from control was shown in PX 606 (MY16∆) with a 0.486% increase in 
median lifespan on average. The other two mutant strains, PX591 (N2∆) and PX595 
(JU775∆) showed an increase of 9.90% and 28.7% respectively.  
 Looking at the magnitude of drug effectiveness between WT and respective daf-
16 mutants, some strains shows increased drug responsiveness with mutation and others 
showed decreased drug responsiveness. The WT strain N2 showed little responsiveness 
with a 0.534% increase in median lifespan, while N2∆ exposed to resveratrol showed an 
increased lifespan of 9.90% as compared to control. Similarly, the CB4856 WT strain 
showed a diminished resveratrol response as compared to its respective mutant, 
CB4856∆ with a 34.7% increase in median lifespan versus the 56.4% increase in 
average median lifespan from control conditions. The WT strain JU775 showed a 
54.5% increase in lifespan while its daf-16 knock-out line had only a 28.7% increase in 
lifespan with resveratrol exposure. Finally, the WT strain MY16 experienced a 41.9% 
increase in lifespan as compared to its control while the mutant line MY16∆ was only 
minimally affected by resveratrol exposure, showing a 0.486% increase in lifespan.  
There are, however, some limitations to this study. While over one-thousand C. 
elegans organisms were utilized in this experimentation, there needs to be further trials 
to ensure reproducibility and validity of the collected data. Some obstacles encountered 
during lifespan data collection included plate contamination and “fogging”, in which 
condensation on the scanner caused obscured image collection in the ALM. Worms on 
plates with fogging or excessive contamination could not be detected by the ALM 
software and had to be excluded from the collected data. 
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Experimental Conclusions 
The antioxidant compound resveratrol was found to increase median lifespan of 
four C. elegans strains and their daf-16 knock-out mutants, however to varying degrees. 
The wildtype N2 and mutant MY16∆ had little responsiveness to the resveratrol 
compound while wildtype JU775 and mutant CB4856∆ both showed an increase in 
median lifespan by over 50%. Interestingly, much of the resveratrol research 
surrounding C. elegans and lifespan changes are conducted with the WT N2 strain, 
which showed the least significant response to the compound as compared to the other 
WT strains in this experiment. This may indicate the need to diversify strain usage for 
drug effectiveness experimentation in C. elegans and potentially spans to other model 
organisms and their various strains as well.  
The variance between the wildtype strains and their daf-16 knockouts with 
resveratrol also differed in magnitude and overall trend. There was no consistency in the 
wildtype or the mutant being more sensitive to resveratrol’s lifespan elongation effects, 
thus it is difficult to determine if resveratrol is acting directly on the Daf-16 pathway or 
by another unknown mechanism. In most mutant lines (excluding MY16∆ with an n=8), 
reveratrol application seemed to at least partially rescue the lifespan diminishing effect 
of knocking out the daf-16 gene. Future research is needed to determine these specific 
intercellular interactions.  
In conclusion, if genetic background was not influencing compound 
effectiveness, one would expect the percent variance in median lifespan across all C. 
elegans strains to be nearly identical, as the magnitude of change would remain 
consistent. With all environmental factors relatively constant throughout the 
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experimentation and the utilization of a control group, the only variance across strain 
and condition throughout this experiment is in the slight genetic differences that exist 
among C. elegans strains, with all organism of the same strain being genetically 
identical. The results indicate that the slight genetic variation across organisms of the 
same species plays an important role in compound effectiveness. Furthermore, the 
varied trends observed between the four strains and their daf-16 mutants indicate that 
identical mutations across slightly genetically varied organism can result in further 
variance in drug response. Such a variance in drug effectiveness demonstrates the 
important role genetics play in drug responsiveness of multicellular organisms, 
potentially extending to a greater call to individualized, personalized medical care in 
humans.  If slight genetic variations across C. elegans result in significant differences in 
treatment effectiveness, there is a high likelihood that the ubiquitous variation among 
human genome sequences also plays a pivotal part in medical treatment efficiency and 
overall success.  
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The Big Picture 
Aspects of patient environment and socioeconomic status play a pivotal role in 
overall well-being and health. Personalized medicine procedures need to include a 
greater level of physician-patient communication in these areas to ensure the most well-
rounded and complete medical care. While the transition toward genetic screening, 
biomarkers and individualized gene therapy has the support of proper technological 
advancements, there are a multitude of factors that influence the potential success of 
personalized medicine in the Western society.  
Economic Considerations 
There is ongoing discourse surrounding personalized medicine analyses and 
diagnoses techniques and their ability to provide an economic value, addressing the 
omnipresent difficulties with innovative new technologies that are accessible and 
affordable. A study conducted by the American College of Medical Genetics and 
Genomics conducted a cost-utility analysis of personalized medicine, utilizing quality-
adjusted life years (QALYs) as the measure of success. It examined the impact a 
personalized and genetic centric approach would have on the top eight causes of 
mortality in the United States (excluding accidents and suicides): heart disease, 
malignant neoplasms, chronic lower respiratory disease, cerebrovascular disease, 
Alzheimer disease, diabetes mellitus, nephritis and influenza/pneumonia (Phillips, 
2014). They also examined the high-expenditure conditions, including heart conditions 
and cancer. Much of the cost to QALY ratio (72%) indicated personalized care provided 
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better health, but with a higher cost. It was found that very few studies indicated an 
overall cost savings (Phillips, 2014). 
Information on clinical utility, economic value, affordability and public health 
implications are essential to assess these new techniques. There is also a call to balance 
innovation and affordability. Responsibility for such a balance is shared among patients, 
providers, industry, payers and professional organizations. These issues are becoming 
more prevalent with the more readily available whole-genome sequencing. There is 
great importance, however, in considering diagnostic value and the need for innovation 
despite economic values and projections. 
Unfortunately, researchers face pressures from the public to develop cell 
therapies that could reach clinics in a relatively short time period and with very little 
funding, making personalized treatment difficult to conceptualize. The transition 
towards personalized medicine may be best facilitated by utilization of patient advocacy 
groups, especially in the early developmental process. They may help by addressing 
concerns around commercialization, especially surrounding the concerns that the 
technologies may not be accessible at a reasonable cost (Bauer, 2017).  
Data Storage and Use 
The Human Gene Mutation Database (HGMD) was created in attempt to collect 
and classify all gene lesions responsible for human inherited disease. While this 
database does not contain somatic or mitochondrial mutations, other platforms such at 
MitoMap and COSMIC cover the genetic gaps (Stenson, 2014). These genome 
databases can be used for extensive meta-analyses on different gene mutations that 
cause human inherited disease, demonstrating mutation evolution among populations 
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along with practical use in clinical settings. Large banks of known mutations allow the 
physicians and technicians to compare known disease causing sequences with those of 
the patient’s genome, proving practical for many diagnoses. The information may also 
be utilized by human molecular geneticist, genome scientists, molecular biologists, and 
those specializing in biopharmaceuticals and bioinformatics (Stenson, 2014).  Evidence 
provided by such technology supports pathological authenticity and detection of 
detrimental gene lesions along with the general importance of a knowledgebase for 
bioinformatics that emphasize personalized genomic testing (Stenson, 2014). 
Harnessing the power and potential of big data could prove essential in the rapidly 
advancing field of bioinformatics. Developers in the field have increasingly been 
transforming cell and gene therapies for the market in efforts to potentially benefit from 
the analysis of large subsets of data (Bauer, 2017) 
Ethical Considerations 
Personalized medicine requires a collective approach and those charged with the 
convergence of bioinformatics and patient data face ethical considerations and many 
possible dilemmas. Ethical challenges are particularly pressing with genomic analysis 
due to vast amounts of sensitive data generated and collected. Furthermore, genetic 
analysis has a certain probabilistic character and the frequent uncertain significance of 
purely considering genetic information leaves potential implications for the patients and 
their relatives (Vos, 2017). Bridging the current translational gap between ethical 
proceedings and genomic research practice is essential before modern medicine can 
transition toward personalized care and the development of successful, large genomic 
databases (Vos, 2017). Broad consent has become the accepted consent model for 
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genomics research, with participants giving permission for a broad range of approved 
but unspecified future research use of their stored samples (Vos, 2017).  It is difficult to 
anticipate the types of risks and benefits when the goal is increasing knowledge and 
technological advances. There are difficulties in determining the level of regulation for 
genetic tests that both protect patients and encourage innovation (Hamburg, 2010).  
To ensure reliability in genetic analysis, research outside clinical medicine must 
first be completed and reproduced. Returning individual genetic results that are 
analytically and clinically valid would be an obligation of those collecting the 
information and analyzing the results. Along with this obligation lies the principal of 
beneficence, respecting the autonomy and reciprocity toward clinical patients and 
research participants as well. There are difficulties surrounding the disclosure of all 
genetic information, however, as too much information may cause adverse 
psychological, social and financial consequences for patients (Vos, 2017). The variable 
interpretation of genetic results makes full disclosure of genetic results cumbersome and 
potentially detrimental. However, unsolicited findings in genetic research may be 
beneficial to later research and mass genetic analysis, aiding the overall advancement of 
knowledge. Moral conflicts may arise with researcher decision making, finding a 
balance between producing generalizable knowledge and warning participants of 
potential harm (Vos, 2017). Addressing the growing concerns surrounding the ethical 
development of personalized medicine and genetic data storage and distribution, there 
needs to be integration and communication between physicians, researchers and the 
public to avoid unethical treatment of patients (Bauer, 2017). The transition toward 
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mainstream personalized, precision medicine is in the ongoing relationship between 
patients and physicians (Schork, 2015).  
Patient History, Environmental Conditions and Race 
 Medical care includes more than disease diagnosis and treatment. Disease 
prevention and increased patient well-being are also important responsibilities of 
medical physicians and researchers. For example, increasing research has been 
conducted on the elongation of human lifespan and, more importantly, health-span. This 
recently coined term represents the amount of time in an organism’s life with optimum 
health. In these years, the individual is generally healthy and free from serious, chronic 
illness.  
 Mental health would be a huge component of successful individualized care, as 
it varies immensely person to person and may impact physical health components as 
well. Those with a greater exposure to stress, for example, have increased rates of heart 
disease, weight gain, diabetes and stroke (Mitchell, 2014). Additionally, the stress 
response is not merely in one’s head. It has been shown that improperly managed, 
chronic stress damages cells and leads to a decreased health-span and often decreased 
overall lifespan as well (Bulterijs, 2015). 
Environmental factors and social hierarchies also have a significant impact on 
overall health, which physicians frequently disregard when diagnosing and creating 
treatment options. The social determinants of health (SDOH) are the socioeconomic 
conditions distributed among populations that influence individual health status. These 
include social structures and economic systems that directly affect physical 
environment, health services and various societal factors (CDC). This is exemplified in 
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various aspects of Westernized society; for instance, African American boys who grow 
up in highly disadvantaged environments have shorter telomeres than boys who grow 
up in highly advantaged environments (Mitchell, 2014). Telomeres are repetitive 
nucleotide sequences at each end of a chromosome, protecting from DNA deterioration 
associated with aging and age-related diseases (Shammas, 2012).  Social environment 
and telomere length (TL) is moderated by genetic variation in the serotonin and 
dopamine pathways. In other words, the environment is directly affecting their DNA. 
This shows a direct gene-social environment interaction using TL as a biomarker for 
stress exposure. Research has suggested many possible behavioral mediators with a 
negative correlation between stress and TL, including stress, mental illness like 
depression, and obesity. Behavior and environment, consequently, are social predictors 
of health that physicians may need to account for in the shift toward personalized care.  
While physicians in the current medical practice do not know how an individual 
patient will respond to a drug treatment, they often rely on information from previous 
studies and experiences to make surface level inferences. According to the American 
Heart Association, heart failure is more common among African Americans than 
Caucasians and the disease symptoms occur at an earlier age, progressing more rapidly 
among blacks (Root, 2003). While this data represents accurate data, physicians relying 
on these statistics when creating preventative care and treatment options to black 
patients may mistreat individuals who do not fall within the statistical range. With few 
exceptions, people classified as “black” have a worse overall health profile than those 
classified as “white” (Root, 2003). Furthermore, while doctors do not know how 
individuals will respond to different drugs, given a correlation between drug response 
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and race, they will invariably begin treatment based on what has worked on the majority 
of those falling in that predetermined category. 
Treating the average and utilizing a one-size-fits-all model of medical care is 
impossible considering the impact of external factors on a cellular and molecular level, 
as individual behavior, exposure, and predetermined biases affect physical health 
immensely. A shift toward personalized care must encompass more than genetic 
analysis and manipulation. Treating a patient as an individual with specific needs 
requires a greater breadth of knowledge around all the factors that directly impact 
human health and how those interplay for each human in a unique manner.  
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Future Directions 
Determining a path to personalized medicine is immensely challenging given the 
many factors that determine individual health and well-being along the endless societal 
considerations that are required for such an approach. The success of personalized 
medicine will depend on accurate and efficient diagnostic tests to identify who will 
benefit from potential targeted therapies (Hamburg, 2010). For example, a test for the 
human epidermal growth factor receptor type 2 (HER2) is currently used in breast 
tumor diagnostics, indicating overexpression and predicting a better response for the 
medication trastuzumab (Hamburg, 2010). Such an indication allows for more effective 
therapy without a trial-and-error approach that a one-type-fits-all treatment approach 
would permit. In order to apply such a technique to other diseases and disorders, there 
must be a collective greater understanding of biomarkers. Randomized control trials 
give evidence for the effectiveness of medical interventions, but such trials include 
patients with predefined characteristics and such a lack of diversity that the results only 
show the effectiveness of a drug in a precise subgroup of people. Medical research 
needs to incorporate a greater diversity of subjects to connect the intricate protein-
protein interactions and mechanisms back to individual genetic background.  
With a greater breadth of knowledge on disease mechanisms and genetic 
linkage, genomic editing technology may be an upcoming component in the 
personalized medicine transition. The potential of the CRISPR (clustered regulatory 
interspaced short palindromic repeats) mechanism for genome editing could change the 
way medical professionals treat genetically linked diseases dramatically. Such 
technology allows for precise gene editing by injection of specified bacterial plasmids, 
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allowing relatively accurate addition or deletion of specific DNA base pairs. As the 
mechanisms become better understood, this method will become more efficient and 
robust with different targeting ranges and specificities (Chen, 2017).  
Finally, a greater understanding of the environmental factors that affect health 
are necessary for the progression toward individualized and highly efficient medical 
care. The effects of mental health, diet, exercise and even socioeconomic level can 
influence individuals at a cellular and genetic level, influencing overall health and well-
being. More medical research must be conducted surrounding the various external 
impacts  
 
Conclusions 
Technological advances and an increasing availability of bioinformatics 
techniques in personalized care have inspired the medical community to expand the 
bounds of modern medicine. With an increasing number of deaths each year due to 
disease with genetic links, the United States may have the opportunity to be in the 
forefront of individualized therapies due to the access to the most innovative technology 
used by some of the most innovative scientists and medical researchers. The quality of 
life of many individuals affected by genetic disorders could be altered drastically, and 
those with underlying genetic mutations that may later cause harm will have a better 
chance of combatting any illness encoded in their genome.  
 The obstacles to reach personalized medical care cannot be ignored, however, 
and the continued discourse around the subject is prudent to developing the most 
efficient individualized care model, both in terms of effective treatment and economic 
 
 
35  
productivity. Thousands of years ago, Hippocrates stated “it is far more important to 
know what person the disease has than what disease the person has”, and the sentiment 
holds true in medicine today (Lee, 2012). This holds true in modern medical care, but 
current care models have shifted away from the treatment of the individual and toward 
the treatment of the average patient, focusing on the list of symptoms rather than their 
root causes. With some economic sacrifices and ethical considerations, personalized 
medicine and genome sequencing technology can open a world of medical care options 
and will result in overall societal health gains that even extend beyond the local bounds. 
Human beings are genetically diverse and, consequently, face unique health concerns. 
Physicians and medical researchers need to aim their focus on individualized, holistic, 
all-encompassing care to provide the most effective treatment options for all.  
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